FLOW (2024) — Trial Summary
FLOW (2024): The FLOW trial evaluated semaglutide, a GLP-1 receptor agonist, for reducing the risk of kidney disease progression in patients with type 2 diabetes and CKD.
References
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121.